CoChat
Sign Up
Cited by 54Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and TreatmentsDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

The Canadian Multicenter Double‐blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis

Heathcote, Jenny E., Cauch-Dudek, Karen, Walker, Valery, Bailey, Robert J., Blendis, Laurence M., Ghent, Cameron N., Michieletti, Pina, Minuk, Gerald Y., Pappas, Chris S., Scully, Linda J., Steinbrecher, Urs P., Sutherland, Lloyd R., Williams, Noel C., Witt-Sullivan, Helga, Worobetz, Lawrence J., Milner, Ruth A., Wanless, Ian R.·1994·Hepatology
DOI 10.1002/hep.1840190512
Open this paper in CoChat — free account

Abstract

Ursodeoxycholic acid, a dihydroxyl bile acid normally present in human beings in minimal amounts, becomes incorporated into the bile salt pool when taken orally. In cholestasis, bile acids are retained in the liver and are hepatotoxic. Ursodeoxycholic acid is the least-known hepatotoxic bile acid, has choleretic properties and is reported to benefit patients with chronic cholestasis. In a nationwide Canadian controlled trial, 222 patients with primary biliary cirrhosis were treated with ursodeoxycholic acid (14 mg/kg/body wt/day) or placebo for 24 mo. Only patients with a diagnosis confirmed by liver biopsy and serum positive for antimitochondrial antibodies were enrolled; 88% were symptomatic on entry. The primary outcome measure was percent change in total serum bilirubin from baseline to final follow-up. Treated patients (111) and controls (111) were comparable with regard to age, gender, biochemical parameters and liver histological condition. Although treatment was not associated with any improvement in symptoms, ursodeoxycholic acid therapy caused the bilirubin to fall significantly within the first 3 mo of therapy (p<0.001). Significant falls in serum alkaline phosphatase, aminotransferases, cholesterol and IgM levels were also noted in the treated group. Improvement in some histological features was observed but there was no difference between the groups in the number of patients who reached the endpoints of death or liver transplantation. Ursodeoxycholic acid, given to patients with primary biliary cirrhosis, leads to an improvement in serum markers of cholestasis. A larger sample size is needed to determine whether ursodeoxycholic acid therapy has a beneficial effect on the survival of patients with primary biliary cirrhosis. (Hepatology 1994;19:1149-1156.)

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.1840190512

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 5

  1. Epstein, 1985, J Hepatol, 1, s49
  2. David, 1985, Z Gastroenterol, 23, 420
  3. , . Immunoglobulin quantitation. In: , , , , eds. Manual of clinical laboratory immunology. Washington, D.C.: American Society for Microbiology, 1992: 71–83.
  4. Zanninelli, 1993, Hepatology, 18, 139a
  5. Hockerstedt, 1990, Transplant Proc, 22, 1499

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Heathcote, J. E., Cauch-Dudek, K., Walker, V., Bailey, R. J., Blendis, L. M., Ghent, C. N., Michieletti, P., Minuk, G. Y., Pappas, C. S., Scully, L. J., Steinbrecher, U. P., Sutherland, L. R., Williams, N. C., Witt-Sullivan, H., Worobetz, L. J., Milner, R. A., & Wanless, I. R.
Affiliations
  • University of Toronto (CA)
  • University of Alberta (CA)
  • Western University (CA)
  • University of Manitoba (CA)
  • University of Ottawa (CA)
  • University of British Columbia (CA)
  • University of Calgary (CA)
  • University of Saskatchewan (CA)
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
1994-05
Volume
19
Issue
5
Pages
1149-1156
ISSN
0270-9139 (ISSN-L)
DOI
10.1002/hep.1840190512
OpenAlex
W7214189001
Cited by
2
References
32
Citations by year
2026: 1
FWCI
0.28
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 7793 d)
Locations
Hepatology (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
ursodeoxycholic acid, primary biliary cirrhosis, cholestasis, serum bilirubin, antimitochondrial antibodies, alkaline phosphatase, transaminases, liver histopathology, liver transplantation, survival, bile acids, hepatotoxicity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review